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The Grapefruit Juice Effect
Rebbeca Leitner
Abstract

A drug interaction is the effect that a substance can have when taken together with a drug. Grapefruit juice has proven
to be a source of interaction with many drugs, causing increased bioavailability, leading to possible toxicity and increased
instances of side effects. This paper discusses the mechanisms of the interaction and the components of grapefruit juice
responsible for the interaction, as well as two classes of drugs that are affected, calcium channel antagonists and HMGCoA reductase inhibitors, and possible ways to avoid the interaction. The mechanisms are inhibition of the enzyme cytochrome P-450 3A4 (CYP3A4) and the transport molecule P-glycoprotein. Furancoumarins are responsible for the interaction. In general, drugs that are affected have a low oral bioavailability and are substrates of CYP3A4. The interaction is
best avoided by not drinking grapefruit juice, or choosing a drug that doesn’t interact. Other possibilities include juice
low in furanocoumarins due to harvest factors, and furanocoumarin free juice. In conclusion, one should exercise caution unless it has been proven that the drugs being taken do not interact with grapefruit juice.

Introduction
In 1997, twenty one percent of the households in
America chose to buy grapefruit juice to drink as their
breakfast beverage. In recent years, the public have realized the importance of including antioxidants in their diets,
and the choice of grapefruit juice, which contains those
compounds, reflects that awareness. Several chronic diseases, most importantly cardiovascular disease and some
cancers, could possibly be prevented by flavenoids and
other components of grapefruit juice. Additionally, there
was a study that was done that showed that grapefruit and
grapefruit juice might promote weight loss (MertensTalcott, et. al. 2006). Due to its possible health benefits, it’s
hard for many people to believe that grapefruit juice can
have an adverse effect when taken together with many
common medications.

A drug interaction is a name given to the effect
that any substance can have when ingested together with
a medication. The possible effects fall into two categories:
pharmacokinetics and pharmacodynamics. Pharmacokinetics includes changes in absorption, distribution, metabolism, and excretion. Pharmacodynamics is the description
of the relationship between the concentration of the drug
and its effect (Mertens-Talcott, et. al. 2006). Grapefruit
juice causes pharmacokinetic interactions. When taken
together with grapefruit juice, many medications display

an increased bioavailability (Fuhr, 1998). This leads to undesired effects, such as decreased efficiacy or toxicity. Increased side effects can occur as well (Mertens-Talcott, et.
al. 2006). The unpleasantness of toxicity can cause patients
to stop taking the drugs, and in extreme cases, toxicity can
even cause death (Bailey, Dresser, 2004).

The phenomenon of the grapefruit juice- drug interaction was discovered by chance in 1989. An experiment was being done to determine if there was an interaction between felodipine, a calcium channel antagonist, and
ethanol. Grapefruit juice was used to mask the taste of the
ethanol. When the results were analyzed, it was discovered that the concentrations of felodipine were significantly higher than those recorded in other experiments, and
the subjects had lower blood pressure and higher instances of unwanted side effects. Further testing was performed to try to discover the cause, and it was found that
the increased concentration was a result of the grapefruit
juice. Since then, numerous drugs have been tested, and
many have been found to interact with grapefruit juice
(Dahan, Altman, 2004). This research paper will discuss the
possible mechanisms behind this phenomenon and the
components of grapefruit juice thought to cause the interaction. The effect and clinical relevance of grapefruit juice
on two classes of cardiovascular medications, calcium
channel antagonists and HMG-CoA reductase inhibitors,
will be analyzed, and several ways of avoiding the interac-
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tions will be explored as well.

drinking just one 300 mL glass of grapefruit juice. The decreased levels indicate that the inhibition is not competitive in nature. (Bailey, Dresser, 2004). Additionally, an investigation that measured CYP3A4 levels after six days of
drinking grapefruit juice recorded greatly decreased
amounts of the enzyme but not of the CYP3A4 mRNA
(Seden, et. al. 2010). Due to these observations, it can be
assumed that grapefruit juice most likely does not inhibit
production of the enzyme. Instead, the juice causes destruction of the enzyme through suicide or mechanismbased inhibition. A component of grapefruit juice is
thought to be converted to a reactive metabolite that
bonds to CYP3A4 and causes inactivation (Bailey, Dresser,
2004).

Methods
Research was done using Touro College’s search
engines such as ProQuest, and MEDLINE, and most frequently, EBSCO. The method of research included evaluating original studies and peer reviewed articles. Keywords
such as “grapefruit juice”, “drug interaction”, and specific
names of drugs were used.

Mechanisms of Action
There are several possible mechanisms that have
been suggested to explain the interaction. Since the interaction only takes place with drugs that are ingested orally,
the mechanism must occur at some point during the digestion process (Mertens-Talcott, et. al. 2006).

If this were the case, synthesis of new enzymes
would be required for restoration of CYP3A4 activity, which
explains the prolonged effect that grapefruit juice can
have. Studies performed with felodipine to determine the
length of time of the effect grapefruit juice support the
theory. It was shown that the maximum effect can still be
observed when the juice is ingested 4 hours before the
drug is administered, and increased levels of felodipine
were still recorded when there was a 24 hour interval between juice and drug intake (Bailey, Dresser, 2004). Recovery times of 72 hours for nisoldipine (Bailey, Dresser, 2004)
and 74 hours for midazolam (Mertens-Talcott, et. al. 2006)
have been observed as well.

Cytochrome P-450 3A4

Cytochrome P450 is a family of enzymes that is
responsible for the breakdown and detoxification of,
among other substances, steroids, environmental carcinogens, and drugs (Girennavar, et. al. 2007). Cytochrome P450 3A4 (CYP3A4) specifically is the isoenzyme highly prevalent in the human digestive system, found in the small
intestine and the liver. Drugs that are metabolized by
CYP3A4 have low oral bioavailability, so only a small
amount of the total that is ingested enters circulation. Because of this, larger doses are administered so that enough
of the drug will be available to cause the desired effect. If
It is interesting to note that the effect of the interCYP3A4 is inhibited, greater oral bioavailability results, and action varies widely among individuals. Those with initial
there is a possibility for undesired effects to occur (Bailey, high CYP3A4 activity have been shown to have greater inDresser, 2004).
hibition than those with naturally lower activity of the enGrapefruit juice has been shown to inhibit CYP3A4 zyme. Therefore, ingestion of grapefruit juice together
in in vitro studies. In one study, the enzyme was tested with an affected drug by these individuals will cause a
with 1%, 10%, and 25% concentrations of different species greater increase in drug concentration than would result in
of grapefruit and pummel juices. Significant inhibition was subjects with low CYP3A4 activity (Mertens-Talcott, et. al.
observed, especially at concentrations of 10% and 25%. At 2006).
those concentrations, inhibition ranged from 96.69% to P-glycoprotein
99.88% (Girennavar, et. al. 2007). In another study that
P-glycoprotein is an ATP-dependent drug transused human liver microsomes, inhibition was observed as
porter. It is an efflux pump located in the small intestine,
well. (Seden, et. al. 2010)
liver, kidneys, and at the blood brain barrier. PGrapefruit juice has been proven to be an inhibitor glycoprotein decreases the bioavailability of many drugs by
of CYP3A4 in in vivo studies as well. Diminished CYP3A4 limiting the amount absorbed from the intestines (Bailey,
enzyme presence, but not mRNA, has been observed after
47

Rebecca Leitner

Dresser, 2004). P-glycoprotein has many substrates, and a actions. According to the current information, it seems to
majority of them overlap with the substrates of CYP3A4. be that the interaction is mainly caused by inhibition of
(Seden, et. al. 2010)
CYP3A4, and that inhibition of P-glycoprotein plays a small
role as well.
The inhibition of P-glycoprotein by grapefruit juice
was first demonstrated by the increased uptake of vinblas- Components of Grapefruit juice Possibly Responsible
tine into Caco-2 cells. Since vinblastine is a substrate of
There are hundreds of chemical components preboth CYP3A4 and P-glycoprotein, no definite conclusion
sent in grapefruit juice. The amounts present in a specific
could be drawn regarding the inhibition of P-glycoprotein
juice depend on a variety of factors, including the genetic
(Mertens-Talcott, et. al. 2006). A study done using human
background of the plant, and the conditions during the
renal proximal cells proved that grapefruit juice does in
growth, maturity, harvesting and processing of the fruit.
fact inhibit P-glycoprotein expression and activity (Romiti,
Most of the constituents are present in other citrus fruits
et. al. 2004) Another study investigated P-glycoprotein
as well, but the amounts of the specific ones differ among
inhibition in Caco-2 cells as well, using colchicine as the
the species. Since juices from numerous sources have disprobe. Grapefruit juice caused increased transport of colplayed interactions with drugs, it seems that the compochicine into the cells. As is the case with vinblastine, colchinent or components that cause the interaction are always
cine is both a CYP3A4 and a P-glycoprotein substrate, so
present. Two of the typically present substances, flavothe cause of the increased uptake can’t be credited solely
noids and furanocoumarins have been presented as the
to P-glycoprotein inhibition. The same study investigated
most probable sources of the grapefruit juice effect (Fuhr,
colchicine permeability in the small intestine of rats in situ.
1998).
It was found that grapefruit juice significantly increased the
permeability of the drug (Dahan, Amidon, 2008). In an ad- Flavonoids
ditional investigation, rats were given talinolol, a substrate
The flavonoid naringin is present in much higher
of P-glycoprotein that does undergo metabolization. Be- levels in grapefruit juice than in other citrus fruit juices.
cause of that, there is no potential for the inhibition of Naringenin, the active metabolite of naringin, is known to
CYP3A4 to interfere with the results. When given together be a strong inhibitor of CYP3A4. Several in vitro studies
with grapefruit juice, concentrations of talinolol were in- have shown that both naringin and naringenin are able to
creased (Bailey, Dresser, 2004).
inhibit the metabolic process of the drugs tested (Fuhr,
1998). Additionally, it has been demonstrated that
naringenin has the ability to inhibit P-glycoprotein in human renal proximal cells (Romiti, et. al. 2004).

Although the in vitro studies demonstrate that
there is a possible inhibition of P-glycoprotein by grapefruit
juice, there have been difficulties in reproducing the
effects in human trials (Seden, et. al. 2010). Digoxin is another drug that is known to be an unmetabolized substrate
of P-glycoprotein. The drug did not display a great change
in bioavailability when administered with grapefruit juice
as compared to water. But since digoxin has a high bioavailability of 70-80%, it is not expected that inhibition of Pglycoprotein would drastically change its concentration
(Bailey, Dresser, 2004).

Although these trials seem promising, human trials
have not gotten conclusive results. Studies that gave subjects naringin in the form of capsules or in solution did not
observe any significant increase in concentrations of the
drugs that were tested. Furthermore, in a study in which
naringin was removed from grapefruit juice, CYP3A4 activity was still inhibited (Fuhr, 1998).

Furanocoumarins

Although research has yet to produce clear proof,
Furanocoumarins are mainly found in the peels of
the above studies demonstrate that there is an interaction
between grapefruit juice and P-glycoprotein. Further stud- grapefruit, but there are significant amounts present in the
ies must be done to determine the extent of the inhibition juice as well (Fuhr, 1998). The most abundant, bergamottin
and how significantly it affects grapefruit juice-drug inter- and its metabolite 6’7’-dihydroxybergamottin (DHB), have
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been identified as CYP3A4 inhibitors. Several in vitro stud- glycoprotein. Finally, since grapefruit juice increases bioaies have proven this.
vailability, the drug must have a normally low bioavailability (Bailey, Dresser, 2004).
The individual furanocoumarins have been isolated
and tested in several studies. In one study, DHB, berga- Dihydropyridine Calcium Channel Antagonists
mottin, paradisin A, bergaptol and geranylcuomarin were
Calcium channel antagonists are vasodilators that
tested for the extent of the inhibition that they caused. It
are used to treat hypertension and other cardiovascular
was found that paradisin A was the strongest, followed by
disorders. Excessive vasodilation can result in headaches,
DHB, then bergamottin, then bergaptol, and finally geranlyswelling of the ankles, and facial flushing. These are not
coumarin (Girennavar, et. al. 2007). Although DHB is not
serious side effects, but they are unpleasant enough to
the strongest, it is the most abundant which is most probacause patients to stop taking the medication, thus leaving
bly why the inhibitory effect is generally attributed to its
their conditions untreated. The more serious side effects
presence. In another study, the furanocoumarins were isoinclude severely low blood and pressure myocardial infarclated and tested as a whole to determine their overall intion (Bailey, Dresser, 2004).
hibitory capacity. When all were combined, the inhibition
Felodipine, the drug with which the grapefruit
was similar to that observed with whole grapefruit juice.
Removing any one of the furanocoumarins from the mix- juice interaction was first observed, has been studied exture decreased the inhibition, which presents the possibil- tensively. It has an absolute bioavailability of 15% (Bailey,
ity that all of furanocoumarins play a role in the grapefruit Dresser, 2004). Over the course of these studies it has
been determined that depending on the amount and timjuice effect (Dahan, Altman, 2004).
ing of the ingestion of grapefruit juice, the concentrations
Further reinforcement of the role of furanocoumaof felodipine can increase to between double and triple
rins can be seen in studies that evaluated the effect of
the usual levels. Greater instances of adverse side effects
furanocoumarin-free grapefruit juice. In one study, most of
were observed as well (Fuhr, 1998).
the furanocoumarins were removed using Aspergillus niNifedipine, another calcium channel antagonist
ger, a strain of fungus. The altered juice was tested in vitro
and found to have a reduced inhibitory effect (Myung, et. with low oral bioavailability, has been shown to be affected
al. 2008). In another study, approximately 99% of the by grapefruit juice as well. In a single case study on a 50
furanocoumarins were removed using food grade solvents year old man, 500 ml of grapefruit juice caused nifedipine
and absorption resins. In vitro, the processed juice did levels to more than double (Nakagawa, Gotu, 2010). Altcause some inhibition, but to a markedly lesser extent than hough this was a single case study, and therefore no defidid whole grapefruit juice. The same study performed a nite conclusions can be drawn, the results match those of
human trial, using felodipine as the probe. It was found larger studies. In another study, sixteen subjects drank 250
that when compared to orange juice, the control, furano- ml of grapefruit juice. The observed result was much less
coumarin-free grapefruit juice had no great effect on the dramatic than that of other studies, but there was an inpharmacokinetics of the drug. This was the first study to crease in bioavailability. This can possibly be explained by
show that the grapefruit juice effect can be credited com- the smaller amount of grapefruit juice administered. In
most other studies, the amount ingested was between 400
pletely to furanocoumarins (Paine, et. al. 2006).
and 500 ml (Odou, et. al. 2005). Other drugs in this class
Drugs that Exhibit an Interaction
that have displayed an interaction are nicardipine, nisodiThe drugs that are affected by grapefruit juice fol- pine, and nitrendipine. The average changes in concentralow a general trend. First of all, because the interaction tion for the above range from 1.5 to four times the normal
occurs in the gastrointestinal tract, the medication must be amount (Bailey, Dresser, 2004).
ingested orally. Second, the drug in question must be eiThe final calcium channel antagonist, amlodipine,
ther metabolized by CYP3A4 or transported by Phas a high oral bioavailability of between 64% and 80%
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(Seden, et. al. 2010). Because of this, it is not expected to
interact with grapefruit juice, and studies support this hypothesis. In the same single case study discussed previously, grapefruit juice did not affect the plasma concentration
of the drug (Nakagawa, Gotu 2010). In a study performed
using twenty volunteers, 240 ml of grapefruit juice was
ingested together with the amlodipine, and an additional
200 ml was taken each day for 8 days following drug administration. Bioavailability was not altered significantly
(Vincent, et. al. 2000).

still statistically significant increase in concentrations
(Reddy, et. al. 2011).
Pitavastatin, a synthetic statin, has a bioavailability
of 60% (Ando, et. al. 2005). It is metabolized not by
CYP3A4, but by CYP2C9, and to some extent by CYP2C8
(Seden, et. al. 2010). In the study that surveyed the effects
of grapefruit juice on atorvastatin in eight subjects,
pitavastatin was tested as well. It was found that the juice
only slightly increased concentrations of pitavastatin in the
blood (Ando, et. al. 2005).

HMG-CoA Reductase Inhibitors

Like pitavastain, pravastatin is not metabolized by
CYP3A4. Pravastatin was surveyed in the second study described for atorvastatin that tested twenty subjects. No
significant effects were recorded (Fukazawa, et. al. 2003).
Two other statins, fluvastatin and rosuvastatin, have not
yet been tested (Seden, et. al. 2010). But fluvastatin is a
CYP2C9 substrate, and rosuvastatin appears not to be a
substrate of either CYP3A4 or P-glycoprotein, so no interactions are predicted (Bailey, Dresser, 2004).

HMG-CoA reductase inhibitors, commonly known
as statins, are used to lower cholesterol. They have the
potential to cause serious toxicity. Side effects range from
diffuse myalgia, or muscle pain, to rhabdomyolysis, which
is severe skeletal muscle degeneration. Acute renal failure
is a possibility as well (Bailey, Dresser, 2004).
Simvastatin, lovastatin, and atorvastatin are all
metabolized by CYP3A4 and therefore have low bioavailability. Simvastatin and lovastatin are inactive forms that are
converted to their active acid forms by esterases. Before
the conversion, they are extensively metabolized by
CYP3A4, resulting in a bioavailability of approximately 5%
(Bailey, Dresser, 2004). In one study, ten volunteers ingested 200 ml of grapefruit juice for two days before and then
together with a dose of simvastatin. The average increase
in concentration was 3.6 times greater than that observed
with water (Lilja, et. al. 2004). In other studies that tested
simvastatin and lovastatin, the average increase was 15fold the normal (Bailey, Dresser, 2004).

How to Avoid the Interaction
The simplest way to avoid the interaction would be
to abstain from drinking grapefruit juice while undergoing
treatment with a drug that is known to, or has been predicted to, interact with grapefruit juice. If the patient has
no interest in giving up the juice, the next best solution
would be to select one of the drugs that have been proven
to have no interaction with the juice. However, if that specific drug is required, and changing to a non-interacting
medication is impossible, there are several methods that
might limit the possibility of an interaction occurring.

Atorvastatin has a bioavailability of 12%. In a study
using eight subjects, grapefruit juice was ingested for three
days before and concomitantly with atorvastatin. Juice was
also administered 4 and 12 hours after drug intake. Concentrations increased between 1.5 and 1.7-fold (Ando, et.
al. 2005). In another study that surveyed twenty subjects,
grapefruit juice was consumed at regular intervals before,
during and after administration of atorvastatin. The average increase that was observed was 83% (Fukazawa, et. al.
2003). Finally, a much larger study was performed using
130 subjects. Patients drank grapefruit daily for ninety days
together with their medication, and there was a small but

As it has been proven that furanocoumarins are
the cause of the grapefruit juice-drug interaction, the ideal
way to minimize the possibility of an interaction occurring
is to limit exposure to furanocoumarins. Below are several
possible ways in which the levels of furanocoumarins can
be reduced.

Harvest Factors and Different Species of Grapefruit
It has been proven that the maturity, location, processing, and storage of grapefruits and grapefruit juice
affects the levels of furanocoumarins present in the final
ingested product. Furanocoumarins are molecules that are
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produced in times of stress so there are many factors that
affect their levels. It was found that furanocoumarin levels
are highest at the beginning of season, and that they decrease throughout the season. In evaluating location, it
was discovered that in general, grapefruits grown in Florida
and California had higher levels than grapefruits grown in
Texas. Hand squeezing versus commercial processing tests
revealed that levels were higher in hand squeezed juice.
Post-harvest, furanocoumarin levels were lowered when
stored at both 24 and 9°C. Finally, levels were evaluated in
processed juice stored in three different types of containers: cans, cardboard bottles, and cartons. All displayed a
decrease in levels over time, but the cartons contained the
highest levels of furanocoumarins (Girennavar, et. al.
2008). Based on these findings, those who would like to
drink grapefruit juice and minimize the possibility for an
interaction should choose commercially processed juice
stored in cans or bottles, and made from organic grapefruits grown in Texas that were harvested late in the season.

Conclusion
As seen in the above studies, grapefruit juice has
the potential to interact with many drugs. Any medication
that is either a substrate of CYP3A4 or transported by Pglycoprotein can possibly be affected when taken together
with grapefruit juice. The components in the juice that are
responsible for the interaction are the furanocoumarins,
which bind to and inactivate CYP3A4 and P-glycoprotein.
Avoidance of the interaction is best accomplished by not
drinking grapefruit juice, or selecting a drug that is known
not to interact. If such actions are not possible, juice that
was processed so as to minimize furanocoumarins might
be a possibility, and there is a chance that furanocoumarinfree grapefruit juice will be developed sometime in the
future.

Since there are so many drugs that have the possibility of interaction, it is important to simply be aware of
this phenomenon. Patients must know to let their doctors
know if they drink grapefruit juice habitually and to ask if
any medications that they are on can interact. Unless it has
Furanocoumarin-Free Grapefruit Juice
been proved that there is no possibility of a reaction, any
Furanocoumarins have been extracted from grape- drug that might interact based on the method in which it’s
fruit juice for studies, but commercial furanocoumarin-free metabolized should be treated as if it is privy to the grapejuice has not been developed. Based on the studies, there fruit juice-drug interaction.
are two possible ways to extract them. In one study, the
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